Spero therapeutics to present data at idweek 2022

Cambridge, mass., oct. 19, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced data presentations for 7 abstracts accepted at the infectious disease society of america (idsa) idweek™ 2022, taking place from october 19 – 23, 2022 in washington, dc.
SPRO Ratings Summary
SPRO Quant Ranking